Results 21 to 30 of about 12,875 (237)

Identification of Barriers Preventing Biosimiliar Oncology Medication Adoption

Medicina, 2022
(1) Background: A biosimilar is a biologic medical product that has been approved by the United States Food and Federal Drug Administration (FDA) and is an almost identical copy of an original biologic product yet manufactured by a different company ...
John Hair, Thomas Maryon, Cristian Lieneck   +2 more
doaj   +1 more source

Emerging Role of Biosimilars in Oncology-Hematology in Saudi Arabia: A Practical Perspective [PDF]

Global Journal on Quality and Safety in Healthcare, 2020
Biologics are significant drivers of globally escalating healthcare costs. Biosimilars have potential to offer cost savings with comparable efficacy and safety to innovator products and increase the access of treatment to more patients.
Mansoor A. Khan, Mohammed A. Aseeri, Majed A. Alshamrani, Abdelmajid H. Alnatsheh, Hani S. Alhamdan   +4 more
doaj   +1 more source

T-cell assays confirm immunogenicity of tungsten-induced erythropoietin aggregates associated with pure red cell aplasia

Blood Advances, 2017
: Immunogenicity of biotherapeutics and the elicitation of anti-drug antibodies are a key concern for their efficacy, pharmacokinetics, and safety.
Tina Rubic-Schneider, Masataka Kuwana, Brigitte Christen, Manuela Aßenmacher, Otmar Hainzl, Frank Zimmermann, Robert Fischer, Vera Koppenburg, Salah-Dine Chibout, Timothy M. Wright, Andreas Seidl, Michael Kammüller   +11 more
doaj   +1 more source

Etanercept biosimilars [PDF]

Rheumatology International, 2014
Etanercept was the first tumour necrosis factor alpha antagonist approved in the USA for the treatment of rheumatoid arthritis, in 1998, and then for other diseases. With the etanercept patent set to expire in the EU in 2015, a number of etanercept copies have reached the production phase and are undergoing clinical trials, with the promise of being ...
Azevedo, Valderilio F., Galli, Nathalia, Kleinfelder, Alais, D’Ippolito, Julia, Urbano, Paulo C. M.   +4 more
openaire   +2 more sources

Physicians’ perceptions of the uptake of biosimilars: a systematic review

BMJ Open, 2020
Objectives To examine physicians’ perceptions of the uptake of biosimilars.Design Systematic review.Data sources MedLine Ovid and Scopus databases at the end of 2018.Eligibility criteria Original scientific studies written in English that addressed ...
Katri Hämeen-Anttila, Kati Sarnola, Merja Merikoski, Johanna Jyrkkä   +3 more
doaj   +1 more source

An open-label extension study to demonstrate long-term safety and efficacy of ABP 501 in patients with rheumatoid arthritis

Arthritis Research & Therapy, 2019
Background ABP 501 was evaluated in a phase 3 single-arm, open-label extension (OLE) study to collect additional safety and efficacy data in patients with rheumatoid arthritis (RA).
Stanley Cohen, Jose L. Pablos, Karel Pavelka, Gerard Anton Müller, Alan Matsumoto, Alan Kivitz, Hui Wang, Eswar Krishnan   +7 more
doaj   +1 more source

The structure-function relationship of disulfide bonds in etanercept

Scientific Reports, 2017
Etanercept is a TNFα receptor Fc fusion protein used for the treatment of rheumatic disease and psoriasis. Physicochemical and functional investigation of process fractions during development of the etanercept biosimilar GP2015 (Erelzi®) revealed a ...
William C. Lamanna, Robert Ernst Mayer, Alfred Rupprechter, Michael Fuchs, Fabian Higel, Cornelius Fritsch, Cornelia Vogelsang, Andreas Seidl, Hansjoerg Toll, Martin Schiestl, Johann Holzmann   +10 more
doaj   +1 more source

Outcomes of adalimumab biosimilar nonmedical switches in children and young adults with inflammatory bowel disease. [PDF]

JPGN Rep
Abstract Objectives Adalimumab biosimilars are as safe and effective compared to the originator. Adult patients with inflammatory bowel disease (IBD) who switched to a biosimilar have comparable outcomes, but pediatric data are limited. This study evaluates clinical outcomes of children and young adults with IBD following a nonmedical, insurance‐driven
Himelstein D, McNicol M, Abdel-Rasoul M, Boyle BM, Michel HK, Maltz R.   +5 more
europepmc   +2 more sources

Biosimilar Use in Breast Cancer Treatment: A National Survey of Brazilian Oncologists' Opinions, Practices, and Concerns

JCO Global Oncology, 2021
PURPOSEBreast cancer is the most common malignancy in Brazilian women, with 66,280 new cases in 2020 (with 20% overexpressing human epidermal growth factor receptor 2 [HER2]).
Heloísa M. Resende, Leandro Ladislau, Ana Carolina F. Cardoso, Juliana Dinéia P. Brandão, Biazi R. Assis, Paola Cardoso, Pedro Henrique A. Marassi, Vivienne Castilho   +7 more
doaj   +1 more source

Can local policies on biosimilars optimize the use of freed resources – experiences from Italy [PDF]

, 2020
There is an increasing need to prescribe biosimilars to fund new medicines and increasing medicine volumes.
Allocati, Eleonora, Godman, Brian, Kwon, Hye-Young, Moorkens, Evelien   +3 more
core   +2 more sources